Implications for the future
Novartis is the pharmaceutical company currently working on getting the drug submitted for approval for pediatric MS worldwide. Children with MS greatly need more effective treatment options. Dr. Simon Schmid, Chief Scientific Officer at Novartis Ireland, said “This pioneering study demonstrates our continued commitment to providing new treatment options for people with MS with the highest need. We look forward to working with health authorities to make this treatment available for people with MS.” With providers and pharmaceutical companies recognizing the need to find better treatment options for children, hopefully pediatric MS will become a bit less challenging for patients in the future.